Enrique Grande, Head of Oncology at MD Anderson Cancer Center, recently shared an article he and his colleagues authored on LinkedIn, titled “Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians” published on Cancer Treatment Reviews.

Authors: Enrique Grandea, Syed A. Hussain, Philippe Barthélémy, Ravindran Kanesvaran, Patrizia Giannatempo, David J. Benjamin, Jason Hoffmann, Alison Birtle.

Enrique Grande: Individualizing first-line treatment for advanced urothelial carcinoma

“Our latest publication is out! – Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians

Enfortumab vedotin + pembrolizumab as the new standard of care (EV-302 trial).
Alternatives include platinum-based chemotherapy + avelumab and nivolumab + cisplatin-gemcitabine for cisplatin-eligible patients.
Treatment decisions should consider efficacy, toxicity profiles, patient characteristics, and preferences.”